Spinal Muscular Atrophy

New England CEPAC

ICER will develop a report assessing the comparative clinical effectiveness and value of onasemnogene abeparvovec (Zolgensma®, Novartis AG/AveXis) and nusinersen (Spinraza®, Biogen) for treatment of spinal muscular atrophy (SMA).

Associated Meetings

March 7, 2019 9:30am-4pm ET

Omni Parker House
60 School Street
Boston, MA 02108

The New England CEPAC will convene to deliberate and vote on ICER's report on treatments for SMA.


Key Dates

Associated Materials

07/31/2018 – 08/17/2018
Open Input Period

08/22/2018

08/22/2018 – 09/12/2018

08/22/2018

09/19/2018

10/17/2018

11/06/2018

12/20/2018

12/20/2018

12/20/2018 – 01/31/2019

02/22/2019

02/22/2019

02/22/2019

03/07/2019

03/07/2019

03/28/2019
Final Evidence Report and Meeting Summary